Additionally, increased ADAM9 levels have been recognized as an independent prognostic marker for overall survival (OS) in stage I NSCLC patients who underwent standard lobectomy and mediastinal N2 lymph node dissection [15]. This evidence concerns the gene ADAM9 and non-small cell lung carcinoma.